BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chiral Quest, LLC And Avantium Technologies Enter Into Collaboration On Chiral Ligand Catalysts


10/19/2005 5:09:43 PM

STATE COLLEGE, Pa., Jan. 20 /PRNewswire-FirstCall/ -- Chiral Quest, Inc. (BULLETIN BOARD: CQST) today announced that it has entered into a partnership with Avantium Technologies to utilize Chiral Quest's array of novel chiral ligand catalysts in Avantium's high throughput experimentation and simulation technology for the biopharmaceutical and fine chemical industries.

Avantium Technologies is an innovation-based company providing rational high throughput product and process R&D solutions to the chemicals and life science industries. Its unique integrated hardware and software platform provides intrinsically scaleable solid-state characterization and chemical development thus allowing rapid and reliable scale-up to pilot plant and production. Chiral Quest offers a broad spectrum of ligands for strategically important asymmetric catalytic reactions. Inclusion of Chiral Quest's proprietary catalysts enhances Avantium's extensive library of commercially available ligands for use in its testing programs.

"We are very pleased to enter this partnership with Avantium," said Chiral Quest CEO and President, Dr. Alan Roth. "Avantium is a leading provider of product and process development services, and their decision to utilize our technology is a vote of confidence in the value and uniqueness of Chiral Quest's products."

"Chiral Quest's ligands will add great value to the diversity of our existing catalyst library and greatly benefit the development technology that we provide to our clients," said Alan Lahaise, Senior Vice President Business Development of Avantium. "Avantium is continually looking for ways to stay in the forefront of biopharmaceutical development technology and we feel that Chiral Quest's novel asymmetric technologies will help us become the leader in this field."

About Chiral Quest

Chiral Quest is a life sciences chemistry company that provides chiral products and asymmetric technologies and services to the pharmaceutical and fine chemical industries. The Company develops chemical catalysts and other products used in the synthesis of desired isomers of chiral molecules. For more information, visit http://www.chiralquest.com/.

About Avantium

Avantium Technologies is an innovation-based company providing rational high throughput product and process R&D solutions to the chemicals and life science industries. Its unique integrated hardware and software platform provides intrinsically scaleable solid-state characterisation and chemical development thus allowing rapid and reliable scale-up to pilot plant and production. Avantium collaborates with, among others, Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Mitsubishi Pharma Corporation, Shell and Eastman Chemicals. The company has its head offices and laboratory in Amsterdam (Avantium Technologies B.V.) and employs a satellite laboratory within Delft University to collaborate with the Dutch Universities in a cutting-edge discovery program. For more information, visit: http://www.avantium.com/.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause Chiral Quest's actual results and experience to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Chiral Quest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Chiral Quest assumes no obligation and does not intend to update these forward-looking statements.

Chiral Quest, Inc.

CONTACT: Alan D. Roth, Ph.D. of Chiral Quest, Inc., +1-814-234-5054; orInvestors, Ritu Baral of The Trout Group, +1-212-477-9007 ext. 25, for ChiralQuest, Inc.; or Lieven De Smedt. CBO of Avantium Technologies BV,+31-20-586-8008, or lieven.desmedt@avantium.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES